ArticleHaematologica2018
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.Annals of hematology · 2025Trial
- A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.Cancer research and treatment · 2024Trial
- Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.Cancer science · 2022Trial
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL.Mediterranean journal of hematology and infectious diseases · 2026Article
- Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.Blood advances · 2025Observational
- How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Blood · 2024Article
- Review
- Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.American journal of hematology · 2023Review
- Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation.Thrombosis and haemostasis · 2022Review
- An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.The American journal of case reports · 2022Article
- Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.Haematologica · 2022Article
- How to Sequence Therapies in Waldenström Macroglobulinemia.Current treatment options in oncology · 2021Review
- The Care of the Leukemic Patients in Times of SARS-CoV-2.Current oncology reports · 2021Review
- Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.Oncology letters · 2021Review
- The role of ibrutinib in COVID-19 hyperinflammation: A case report.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Current and novel BTK inhibitors in Waldenström's macroglobulinemia.Therapeutic advances in hematology · 2021Article
- Management of Waldenström macroglobulinemia in 2020.Hematology. American Society of Hematology. Education Program · 2020Review
- Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.The oncologist · 2020Article
- Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.HemaSphere · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.